Published on
December 2, 2025
- 14:10 GMT
VERIGRAFT Reports Strong Safety and Favorable Clinical Outcomes in First-in-Human TECVI-1 Trial
TECVI-1 showed very good safety outcomes and sustained clinical improvement through 12 months. GOTHENBURG, SWEDEN, December 2, 2025 /EINPresswire.com/ -- VERIGRAFT AB today announced results from its first-in-human TECVI-1 clinical trial evaluating the …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
